Previous 10 | Next 10 |
BURLINGTON, Mass. and JERUSALEM, Jan. 11, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that a major pri...
BrainsWay ( NASDAQ: BWAY ), a developer of non-invasive treatments for brain disorders, has settled an unfair competition litigation with medical technology company Neuronetics ( NASDAQ: STIM ). The litigation had been filed by STIM in the district of Delaware against BrainsWa...
BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported that it has settled litigation filed by...
BURLINGTON, Mass. and JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported a recent open market purchase of Brains...
BURLINGTON, Mass. and JERUSALEM, Nov. 28, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported that David Zacut, M.D., BrainsWay...
BrainsWay Ltd. (BWAY) Q3 2022 Results Earnings Conference Call November 16, 2022, 08:30 AM ET Company Participants Bob Yedid - Investor Relations, LifeSci Advisors Christopher von Jako - President and Chief Executive Officer Scott Areglado - Chief Financial Offic...
BrainsWay ( NASDAQ: BWAY ) stock fell ~29% on Wednesday after Q3 results missed estimates. Net loss and total comprehensive loss widened to -$5.04M, compared to -$1.80M in Q3 2021. Revenue declined -35.89% Y/Y to $5.17M. "While the current macroeco...
Brainsway press release ( NASDAQ: BWAY ): Q3 GAAP EPS of -$0.15 misses by $0.09 . Revenue of $5.17M (-35.9% Y/Y) misses by $3.28M . As of September 30, 2022, BrainsWay’s Deep TMS™ installed base was 851 total systems, a 19% increase from the insta...
BURLINGTON, Mass. and JERUSALEM, Nov. 16, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported third quarter 2022 financial resu...
BURLINGTON, Mass. and JERUSALEM, Nov. 03, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that Preme...
News, Short Squeeze, Breakout and More Instantly...
2024-07-16 23:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BURLINGTON, Mass. and JERUSALEM, June 17, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced its broad market...